FGFR2 as a Candidate Target for Synovial Sarcoma Therapy?

General Blog
1

The following study looked at how the translocation associated oncogene SYT-SSX2 reprograms stem cells to become malignant in synovial sarcoma:

http://www.ncbi.nlm.nih.gov/projects/geo/query/acc.cgi?acc=GSE26565

They suggest FGFR2 is a promising target for future synovial sarcoma therapy...


2

The following trial might be of interest:

http://clinicaltrials.gov/ct2/show/NCT01283945?term=E-3810-I-01&rank=1

More on this drug:

http://www.eosmilano.com/upload/allegati/1145_poster_191,_berlino_eortc-nci-aacr_16-19_11_2010.pdf